SB365, Pulsatilla saponin D, suppresses the growth of gefitinib-resistant NSCLC cells with Met amplification

Oncology Reports

Volumn 32, Issue 6, 2014, Pages 2612-2618

  Jang, Won Jun ^a   Park, Byoungduck ^a   Jeong, Gil Saeng ^a   Hong, Soon Sun ^b   Jeong, Chul Ho ^a  

^a Keimyung University   (South Korea)

^b Inha University School of Medicine   (South Korea)

Author keywords

Drug resistance; EGFR; Gefitinib; Met; Saponin D; SB365

Indexed keywords

GEFITINIB; SAPONIN DERIVATIVE; SB 365; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; MET PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; SAPONIN;

ANCHORAGE INDEPENDENT GROWTH; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; FLOW CYTOMETRY; GENE AMPLIFICATION; HCC827GR CELL LINE; HUMAN; HUMAN CELL; INHIBITION KINETICS; MIGRATION INHIBITION; NON SMALL CELL LUNG CANCER; PLANT ROOT; PROTEIN PHOSPHORYLATION; PULSATILLA; PULSATILLA KOREANA; SIGNAL TRANSDUCTION; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; PROTO-ONCOGENE PROTEINS C-MET; PULSATILLA; QUINAZOLINES; SAPONINS; SIGNAL TRANSDUCTION;

EID: 84914674834     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3528     Document Type: Article

References (35)

1. Jung KW, Park S, Kong HJ, et al: Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci 25: 1113-1121, 2010.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
3. Owonikoko TK, Ragin CC, Belani CP, et al: Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 25: 5570-5577, 2007
4. Sher T, Dy GK and Adjei AA: Small cell lung cancer. Mayo Clin Proc 83: 355-367, 2008.
5. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246, 2003.
6. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M and Tanimoto M: Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based metaanalysis of randomised trials. Ann Oncol 15: 1782-1789, 2004
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132, 2005
8. Laskin JJ and Sandler AB: Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 30: 1-17, 2004
9. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010.
10. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010.
11. Rosell R, Moran T, Queralt C, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967, 2009
12. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73, 2005
13. Bean J, Brennan C, Shih JY, et al: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104: 20932-20937, 2007
14. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007.
15. Yano S, Wang W, Li Q, et al: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68: 9479-9487, 2008.
16. Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3: 75ra26, 2011.
17. Engelman JA, Zejnullahu K, Gale CM, et al: PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67: 11924-11932, 2007.
18. Tang Z, Du R, Jiang S, et al: Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 99: 911-922, 2008.
19. Saha SK and Khuda-Bukhsh AR: Molecular approaches towards development of purified natural products and their structurally known derivatives as efficient anti-cancer drugs: current trends. Eur J Pharmacol 714: 239-248, 2013.
20. Youn HJ, Lakritz J, Kim DY, Rottinghaus GE and Marsh AE: Anti-protozoal efficacy of medicinal herb extracts against Toxoplasma gondii and Neospora caninum. Vet Parasitol 116: 7-14, 2003.
21. Hong SW, Jung KH, Lee HS, et al: SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway. Cancer Sci 103: 1929-1937, 2012.
22. Hong SW, Jung KH, Lee HS, et al: SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities. Carcinogenesis 34: 2156-2169, 2013.
23. Son MK, Jung KH, Hong SW, et al: SB365, Pulsatilla saponin D suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the AKT/mTOR signalling pathway. Food Chem 136: 26-33, 2013.
24. Son MK, Jung KH, Lee HS, et al: SB365, Pulsatilla saponin D suppresses proliferation and induces apoptosis of pancreatic cancer cells. Oncol Rep 30: 801-808, 2013.
25. Kim Y, Bang SC, Lee JH and Ahn BZ: Pulsatilla saponin D: the antitumor principle from Pulsatilla koreana. Arch Pharm Res 27: 915-918, 2004.
26. Ghosh G, Yan X, Lee AG, Kron SJ and Palecek SP: Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array. Biosens Bioelectron 26: 424-431, 2010.
27. Freedman VH and Shin SI: Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 3: 355-359, 1974.
28. Zhao J: Nutraceuticals, nutritional therapy, phytonutrients, and phytotherapy for improvement of human health: a perspective on plant biotechnology application. Recent Pat Biotechnol 1: 75-97, 2007.
29. Taylor WG, Elder JL, Chang PR and Richards KW: Microdetermination of diosgenin from fenugreek (Trigonella foenum-graecum) seeds. J Agric Food Chem 48: 5206-5210, 2000.
30. Price KR, Johnson IT and Fenwick GR: The chemistry and biological significance of saponins in foods and feedingstuffs. Crit Rev Food Sci Nutr 26: 27-135, 1987.
31. 4 hydrolase. Cancer Res 69: 5584-5591, 2009.
32. 4 hydrolase. Cancer Res 70: 9755-9764, 2010.
33. Jung SK, Lee KW, Byun S, et al: Myricetin inhibits UvB-induced angiogenesis by regulating PI-3 kinase in vivo. Carcinogenesis 31: 911-917, 2010.
34. Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925, 2003.
35. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF and Testa JR: Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 98: 247-252, 2001.